Skip to main content

Table 3 Clinicopathologic and molecular characteristics of colorectal cancers in patients with stage II or stage III colorectal cancers who underwent surgery alone or received fluoropyrimidine-based adjuvant chemotherapy

From: The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy

  CIMP-low/negative
Surgery alone
(n = 39)
CIMP-low/negative
Surgery + CRx
(n = 61)
CIMP-high
Surgery alone
(n = 7)
CIMP-high
Surgery + CRx
(n = 17)
Age (yrs)     
   Mean ± SD 63.4 ± 11.0 58.7 ± 10.8 72.9 ± 7.1 60.1 ± 10.7
   Median (Range) 66.0 (42 - 83) 64.0 (36 - 75) 75.0 (63 - 82) 63.0 (33 - 72)
Gender (%)     
   Male 23 (59.0) 34 (55.7) 3 (42.9) 11 (64.7)
   Female 16 (41.0) 27 (44.3) 4 (57.1) 6 (35.3)
Tumor site (%)     
   Proximal 14 (35.9) 19 (31.1) 6 (85.7) 12 (70.6)
   Distal 25 (64.1) 42 (68.9) 1 (14.3) 5 (29.4)
Lymph node metastasis (%)    
   Absent 37 (94.9) 25 (41.0) 6 (85.7) 10 (58.8)
   Present 2 (5.1) 36 (59.0) 1 (14.3) 7 (41.2)
AJCC stage (%)     
   II 37 (94.9) 25 (41.0) 6 (85.7) 10 (58.8)
   III 2 (5.1) 36 (59.0) 1 (14.3) 7 (41.2)
Differentiation (%)     
   Well/Moderate 34 (87.2) 56 (91.8) 6 (85.7) 9 (52.9)
   Poor/Mucinous 5 (12.8) 5 (8.2) 1 (14.3) 8 (47.1)
Mucinous histology (%)     
   Absent 36 (92.3) 59 (96.7) 7 (100.0) 12 (70.6)
   Present 3 (7.7) 2 (3.3) 0 (0.0) 5 (29.4)
BRAF (%)     
   Wild type 39 (100.0) 61 (100.0) 4 (57.1) 14 (82.4)
   Mutation 0 (0.0) 0 (0.0) 3 (42.9) 3 (17.6)
KRAS (%)     
   Wild type 22 (56.4) 45 (73.8) 3 (42.9) 11 (64.7)
   Mutation 17 (43.6) 16 (26.2) 4 (57.1) 6 (35.3)
MGMT methylation (%)     
   Absent 26 (66.7) 47 (77.0) 3 (42.9) 5 (29.4)
   Present 13 (33.3) 14 (23.0) 4 (57.1) 12 (70.6)
MSI status (%)     
   MSS/MSI-low 33 (84.6) 50 (82.0) 4 (57.1) 3 (17.6)
   MSI-high 6 (15.4) 11 (18.0) 3 (42.9) 14 (82.4)
  1. CIMP CpG island methylator phenotype, CRx Fluoropyrimidine-based adjuvant chemotherapy
  2. MSI microsatellite instablity, MSS microsatellite stable